# Talat Imran

> Talat Imran is the CEO of Rani Therapeutics, a clinical-stage biotech company pioneering the RaniPill - a swallowable capsule that delivers injectable biologics painlessly through the intestinal wall. Son of prolific medical device inventor Mir Imran, Talat leads a company racing to replace needles with a pill, with applications spanning obesity, immunology, and rare disease. A computer scientist turned venture capitalist turned biotech CEO, he brings an unusual tech-meets-biology perspective to one of pharma's thorniest unsolved problems.

- **Role:** Chief Executive Officer at Rani Therapeutics
- **Organizations:** Rani Therapeutics, InCube Ventures, VentureHealth, Venture Web Partners, The Angels' Forum
- **Nationality:** American
- **Education:** B.A. in Computer Science, University of California, Santa Cruz, Attended, Foothill College
- **Known for:** Led Rani Therapeutics through its Nasdaq IPO in July 2021, raising $84.3 million, Grew Rani Therapeutics to a 110-person clinical-stage biotech company, Secured research partnership with Chugai Pharmaceutical for oral biologic delivery

## Career timeline

- **2005** — Joined The Angels' Forum (TAF) to manage deal flow with tech, consumer, and healthcare startups
- **2006** — Founded and served as CEO of Venture Web Partners, a web application development firm
- **2006-2016** — CEO of Venture Web Partners; also worked with InCube Ventures as Managing Director evaluating early-stage healthcare technologies
- **c.2010** — Co-founded VentureHealth to improve capital access for healthcare innovators; created opportunities for accredited physician investors
- **2014** — Joined Rani Therapeutics as Vice President of Strategy, becoming a key member of the executive team
- **2021-07** — Rani Therapeutics IPO on Nasdaq (ticker: RANI), raising $84.3M at $11/share
- **2021-06-22** — Appointed Chief Executive Officer and Director of Rani Therapeutics, with founder Mir Imran transitioning to Executive Chairman
- **2024** — Established partnership with ProGen for RT-114 RaniPill formulation targeting obesity treatment
- **2025-05** — Entered Research Agreement with Chugai Pharmaceutical for two molecules
- **2026-01** — Initiated Phase 1 study for GLP-1/GLP-2 dual agonist oral delivery (RT-114)

## Achievements

- Led Rani Therapeutics through its Nasdaq IPO in July 2021, raising $84.3 million
- Grew Rani Therapeutics to a 110-person clinical-stage biotech company
- Secured research partnership with Chugai Pharmaceutical for oral biologic delivery
- Established transformative collaboration with ProGen for oral GLP-1/GLP-2 obesity treatment
- Initiated Phase 1 clinical trial for RT-114 (oral GLP-1/GLP-2 dual agonist) in January 2026
- Co-founded VentureHealth to bridge early-stage capital gaps in healthcare innovation
- Built and managed InCube Ventures portfolio of healthcare technology investments

## Latest updates

- **2026-01** — Rani Therapeutics initiated Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist targeting obesity
- **2025-05** — Announced Research Agreement with Chugai Pharmaceutical for two undisclosed molecules using RaniPill platform
- **2024-12** — Company reported $27.6 million in cash and marketable securities as of December 31, 2024
- **2024-10** — Talat Imran participated in fireside chat at 2024 Maxim Healthcare Virtual Summit
- **2024** — Established partnership with ProGen for RT-114 RaniPill formulation containing PG-102 for obesity treatment

## Links

- Website: https://ranitherapeutics.com
- LinkedIn: http://www.linkedin.com/in/talat
- Twitter/X: https://x.com/Imran15Talat

---

Profile page: https://yespress.io/talat-imran
Published by YesPress — https://yespress.io
Last updated: 2026-05-14